A detailed history of Van Eck Associates Corp transactions in Galapagos Nv stock. As of the latest transaction made, Van Eck Associates Corp holds 753 shares of GLPG stock, worth $20,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
753
Previous 1,209 37.72%
Holding current value
$20,150
Previous $30,000 23.33%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$24.2 - $30.67 $11,035 - $13,985
-456 Reduced 37.72%
753 $23,000
Q1 2024

Apr 30, 2024

BUY
$32.2 - $42.44 $1,996 - $2,631
62 Added 5.41%
1,209 $38,000
Q4 2023

Feb 05, 2024

BUY
$31.87 - $40.71 $6,087 - $7,775
191 Added 19.98%
1,147 $47,000
Q1 2023

May 03, 2023

SELL
$36.5 - $48.0 $1,533 - $2,016
-42 Reduced 4.21%
956 $37,000
Q4 2022

Feb 08, 2023

BUY
$37.44 - $46.51 $8,611 - $10,697
230 Added 29.95%
998 $44,000
Q3 2022

Oct 27, 2022

BUY
$42.27 - $57.6 $32,463 - $44,236
768 New
768 $33,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.76B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.